Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very high-dose atorvastatin before elective angioplasty
IRCT2017011831073N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atorvastatin in myocardial infarction (MI), contrast-induced nephropathy (CIN) and coronary arteriosclerosis, sponsored by Tehran University of Medical Sciences. Primary endpoints: Acute myocardial infarction after elective stenting and Contrast-induced nephropathy after elective stenting. Started Aug 2016; status: completed.
02
Drugs
atorvastatin
03
Conditions
myocardial infarction (MI)contrast-induced nephropathy (CIN)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT2017011831073N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017011831073N2.